Key result
PAH links to metabolic and inflammatory hepatopathy driven by hepatocyte reprogramming and macrophage complement signaling.
Why the study?
Hepatic dysfunction predicts adverse outcomes in pulmonary arterial hypertension and right ventricular failure, but the cell-specific effects on the human liver remain poorly defined.
Observational (n=9)
Answers are grounded in this paper and cite their sources.
Reveals distinct metabolic and inflammatory changes in liver due to pulmonary arterial hypertension, suggesting a link to right ventricular failure severity.
BACKGROUND. Right ventricular failure (RVF) is a major determinant of mortality in pulmonary arterial hypertension (PAH), and hepatic dysfunction predicts adverse outcomes. However, the cell-specific effects of PAH/RVF on the human liver remain poorly defined. METHODS. We performed single-nucleus RNA sequencing of autopsy-derived liver tissue from 5 PAH patients and 4 non-PAH controls and compared these findings with publicly available single-nucleus RNA sequencing datasets from non-alcoholic steatohepatitis (NASH) and Fontan-associated liver disease (FALD). Transcriptomic analyses were integrated with histologic assessment, mitochondrial-enriched proteomics, and correlated with clinical markers of PAH/RVF severity. RESULTS. PAH livers showed cell-specific metabolic, inflammatory, and fibrotic remodeling distinct from NASH and FALD. PAH hepatocytes exhibited a hypoxia-adapted, Warburg-like metabolic phenotype with reduced fatty acid metabolism, gluconeogenesis, cytochrome P450 activity, and ketone metabolism. PAH endothelial cells demonstrated increased glycolytic pathway activity and disrupted adhesion/barrier signaling. PAH hepatic stellate cells displayed HIF-1 and PI3K-Akt pathway activation, and increased IL6 expression, which resulted in central vein fibrotic remodeling. PAH macrophages showed complement activation with reduced JAK-STAT signaling. Finally, HSC HIF-1 activity correlated with clinical markers of PAH/RVF severity. CONCLUSION. PAH induces a distinct metabolic and inflammatory hepatopathy characterized by hepatocyte metabolic reprogramming, HSC activation, and macrophage complement signaling. These findings support PAH-associated hepatopathy as a disease-specific end-organ phenotype linked to RVF severity.
No takes yet. Share an insight, caveat, or question.
Blake et al. (2026) conducted an observational in Pulmonary Arterial Hypertension (n=9). Pulmonary Arterial Hypertension vs. Non-PAH controls was evaluated on Cell-specific transcriptomic alterations in liver tissue. Pulmonary arterial hypertension induces a distinct metabolic and inflammatory hepatopathy characterized by hepatocyte metabolic reprogramming, hepatic stellate cell activation, and macrophage complement signaling.
Synapse has enriched 10 related papers. Consider them for comparative context: